ASCO, COA to Congress: Part B Drug Model Is Bad Medicine

Representatives of the American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) urged Congress to stop a Medicare Part B demonstration project, sale which they say will have a detrimental effect on cancer patients’ access to care, in testimony to the U.S. House of Representatives Committee on the Budget on Sept. 7.

The Center for Medicare & Medicaid Innovation’s (CMMI)-proposed Part B demonstration project would reduce reimbursement rates to oncology practices through the Average Sales Price (ASP) formula from ASP plus 6% to ASP plus 2.5% with an additional $16.80 flat fee per drug per day. According to ASCO, budget sequestration would further reduce the rate of reimbursement to ASP plus 0.86% and a flat fee of $16.53 per drug per day.

“We strongly believe that if CMS [the Centers for Medicare & Medicaid Services] is intent on moving forward with the proposal, that Congress will need to intervene to prevent serious negative consequences for cancer patients who are Medicare beneficiaries throughout the United States,” said Daniel F. Hayes, MD, FASCO, the president of ASCO, in his testimony.

Read Full Article Here >>